Assess the Long-term Effectiveness and Safety of Amevive (Alefacept) in Subjects With Moderate to Severe Chronic Plaque Psoriasis
NCT ID: NCT00795353
Last Updated: 2013-02-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
64 participants
OBSERVATIONAL
2008-07-31
2011-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1. Amevive Exposure
Canadian subjects with moderate to severe chronic plaque psoriasis
Amevive exposure
Commercial alefacept prescribed by Physician
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Amevive exposure
Commercial alefacept prescribed by Physician
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Subjects with a history of cancer except for adequately treated basal cell carcinoma (maximum of 2 lesions)
* Subjects with any active cancer, including skin cancer
* Subjects having a serious local infection (eg. cellulitis, abscess) or serious systemic infection (eg. pneumonia, septicemia, tuberculosis), within the 3 months prior to the first dose of alefacept.
* Subjects known to be infected with the AIDS virus
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Astellas Pharma Canada, Inc.
INDUSTRY
Astellas Pharma Inc
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Use Central Contact
Role: STUDY_DIRECTOR
Astellas Pharma Canada, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Edmonton, Alberta, Canada
Winnipeg, Manitoba, Canada
Winnipeg, Manitoba, Canada
Bathurst, New Brunswick, Canada
Quispamsis, New Brunswick, Canada
St. John's, Newfoundland and Labrador, Canada
St. John's, Newfoundland and Labrador, Canada
Halifax, Nova Scotia, Canada
Hamilton, Ontario, Canada
London, Ontario, Canada
London, Ontario, Canada
Markham, Ontario, Canada
Oakville, Ontario, Canada
Peterborough, Ontario, Canada
Toronto, Ontario, Canada
Waterloo, Ontario, Canada
Welland, Ontario, Canada
Alma, Quebec, Canada
Montreal, Quebec, Canada
Québec, Quebec, Canada
Saint-Hyacinthe, Quebec, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A.W.A.R.E.-2
Identifier Type: -
Identifier Source: org_study_id